Status:
COMPLETED
Relapse Prevention Study Of Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder
Lead Sponsor:
Pfizer
Conditions:
Major Depressive Disorder
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The primary purpose of this study is to compare the long-term efficacy and safety of desvenlafaxine succinate sustained release versus placebo in adults with Major Depressive Disorder, using a randomi...
Eligibility Criteria
Inclusion
- Adult, outpatient with primary diagnosis of Major Depressive Disorder (depressive symptoms for at least 30 days prior to screening)
- Hamilton Psychiatric Rating Scale for Depression (HAM-D 17) total score of \>= 20
- Clinical Global Impressions Scale-Severity (CGI-S) score of \>= 4.
Exclusion
- Significant risk of suicide as assessed by clinician judgment, HAM-D17 and Columbia Suicide-Severity Rating Scale scores.
- Past treatment with desvenlafaxine succinate sustained release.
- Other eligibility criteria also apply.
Key Trial Info
Start Date :
June 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2011
Estimated Enrollment :
874 Patients enrolled
Trial Details
Trial ID
NCT00887224
Start Date
June 1 2009
End Date
March 1 2011
Last Update
November 21 2014
Active Locations (90)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Beverly Hills, California, United States, 90210
2
Pfizer Investigational Site
Encino, California, United States, 91316
3
Pfizer Investigational Site
Los Alamitos, California, United States, 90720
4
Pfizer Investigational Site
Orange, California, United States, 92868